The purpose of this report is to summarize information on oxaliplatin, a drug recently approved by the U.S. Food and Drug Administration. Information provided includes regulatory history, study design, efficacy and safety results, and pertinent literature references.
INTRODUCTION
Oxaliplatin (Eloxatin ™ ; Sanofi Synthelabo Inc.; New York, NY) ( Fig. 1 ) is a platinum (II) analog similar to the approved drugs cisplatin and carboplatin. Its mechanism of action involves the formation of DNA adducts and inhibition of DNA synthesis. Oxaliplatin has been evaluated, both in vitro and in vivo, alone and in combination with 5-fluorouracil (FU), in several tumor models including human breast, colon, and mammary tumors. The oxaliplatin/5-FU combination consistently has demonstrated greater activity than that which is seen with either drug alone.
A New Drug Application (NDA) for a first-line indication in metastatic colorectal cancer was submitted to the U.S. Food and Drug Administration (FDA) in February 1999. The NDA comprised two multicenter, randomized, controlled clinical trials. In one study, 200 patients were randomized to receive either oxaliplatin followed by 5-FU and leucovorin (LV) daily for 5 days as a chronomodulated infusion [1] or the same regimen without oxaliplatin. In the second study, 420 patients were randomized to receive either the FOLFOX 4 regimen, consisting of oxaliplatin and 5-FU/LV (Table 1 and Fig. 2 ), or 5-FU/LV alone. The primary end points were response rate (first study) and progression-free survival (second study).
The application was presented to the Oncologic Drugs Advisory Committee in March 2000. The Committee noted that, although oxaliplatin demonstrated antitumor activity, no survival benefit was observed. As other treatment regimens had produced survival benefit in first-line metastatic colorectal cancer treatment, the committee recommended non-approval.
Subsequent meetings between the FDA and the sponsor produced a plan for a study comparing oxaliplatin with infusional 5-FU/LV (the de Gramont regimen) [2] and with a combination of oxaliplatin and infusional 5-FU/LV as second-line therapy for colorectal cancer. An infusional 5-FU regimen was chosen because of evidence that infusional 5-FU treatment might induce objective responses in patients who had previously progressed on i.v. bolus 5-FU [3] and because of the different toxicity spectrums of infusional versus bolus 5-FU [4] . That study was granted "Fast Track" designation, meaning that, in addition to scheduled meetings, the sponsor had the option to submit the data for an NDA application in sections over time.
Review of data from the above study, summarized below, led to accelerated approval of oxaliplatin on August 
PRESCRIBING OXALIPLATIN
The recommended dose of oxaliplatin in combination with infusional 5-FU/LV is 85 mg/m 2 i.v. over 2 hours in 250-500 ml of dextrose 5% in water (D5W). LV, 200 mg/m 2 , is administered by an i.v. infusion simultaneously over 2 hours in a separate bag using a Y-line. 5-FU follows the oxaliplatin and LV, first as a bolus injection over 2-4 minutes at a dose of 400 mg/m 2 , and then as a continuous infusion in 500 ml of D5W over 22 hours at a dose of 600 mg/m 2 . LV is repeated on day 2 of the cycle without oxaliplatin. The 5-FU 400-mg/m 2 bolus and 600-mg/m 2 22-hour infusion are repeated on day 2, after completion of the day 2 LV infusion ( Fig. 2) . The cycle is repeated every 2 weeks (Table 1 and Fig. 2 ). See full prescribing details in the package insert [5] .
ACCELERATED APPROVAL CLINICAL TRIAL

Methods
A single, large, multicenter, randomized trial enrolled 463 patients with metastatic colorectal carcinoma. Response rate was the prespecified end point for potential accelerated approval. TTP was a secondary end point. The prespecified primary comparison was between the 5-FU/LV regimen and the 5-FU/LV/oxaliplatin combination regimen (arm A versus arm C). The null hypothesis was tested at a two-tailed level of p = 0.05, using the log-rank test. The three arms were well balanced for prognostic factors. The treatment could have been continued for up to 1 year. However, a maximum number of 18 cycles (16 on the oxaliplatin combination arm) were actually administered.
Response Rate
Responses were evaluated using the Response Evaluation Criteria in Solid Tumors [6] . An independent consulting group reviewed the radiological studies. That group's response assessment, based on radiographic measurements, was prespecified in the analysis plan as the basis for the primary analysis of response rate. The independent reviewer was blinded to the treatment arm of the patients and the investigator's assessments of response (including investigator choice of target lesions). The FDA subsequently conducted an independent response rate review. The results of the FDA analysis of response rate are summarized in Table 2 .
TTP
TTP evaluation was submitted in two separate analyses, one based on investigator data (counting radiographic and clinical progression as well as death as events) and the other limited to radiographic data for progressive disease as assessed by an independent radiology group. The latter was the prespecified primary analysis of TTP. With approximately 50% of the potential TTP events recorded, a longer TTP of almost 2 months was noted for the oxaliplatin combination arm compared with the 5-FU and LV control arm by both the sponsor and FDA analyses (Table 3 ). This analysis excluded 82 (18%) patients by censoring them at baseline. Twenty-five of those patients had radiographic assessments performed beyond baseline by the investigator, but those radiographs were either not submitted for independent radiologist review or were not deemed evaluable by the radiologist. The other censored patients did not have any radiographic assessments beyond baseline. An exploratory analysis was performed incorporating the radiographic progression data from the investigator analysis, This is not an intention-to-treat analysis. Events were limited to radiographic disease progression documented by independent review of radiographs. Clinical progression was not included in this analysis, and 18% of patients were excluded from the analysis based on unavailability of the radiographs for independent review. Table 4 . Adverse event experience (≥5% of all patients and with ≥1% NCI grade 3/4 events) 98  41  100  46  99  73  Neuropathy -total  17  0  76  7  74  7  Acute  10  0  65  5  56  2  Persistent  9  0  43  3  48  6  Fatigue  52  6  61  9  68  7  Diarrhea  44  3  46  4  67  11  Nausea  59  4  64  4  65  11  Vomiting  27  4  37  4  40  9  Stomatitis  32  3  14  0  37  3  Abdominal pain  31  5  31  7  33  4  Fever  23  1  25  1  29  1  Anorexia  20  1  20  2  29  3  Dyspnea  11  2  13  7  20  4  Back pain  16  4  11  0  19  3  Coughing  9  0  11  0  19  1  Edema  13  1  10  1  15  1  Pain  9  3  14  3  15  2  Injection site reaction  5  1  9  0  10  3  Thromboembolism  4  2  2  1  9  8  Hypokalemia  3  1  3  2  9  4  Dehydration  6  4  5  3  8  3  Chest pain  4  1  5  1  8  1  Febrile neutropenia  1  1  0  0  6  6  Gastroesophageal reflux  3  0  1  0  5  2  Anemia  68  2  64  1  81  2  Leukopenia  34  1  13  0  76  19  Neutropenia  25  5  7  0  73  44  Thrombocytopenia  20  0  30  3 Drug Approval Summaries when available, where data were unavailable from the independent review. Twelve percent of patients were censored at baseline by this method. The difference in TTP remained at 2 months in the exploratory analysis, giving support to the improvement in TTP as evaluated in the independent analysis.
5-FU/LV
Safety
Common adverse events associated with the combination treatment included peripheral neuropathy, fatigue, diarrhea, nausea, vomiting, stomatitis, and abdominal pain (Table 4 ). Neutropenia was the major hematologic toxicity. The diarrhea and myelosuppression normally associated with 5-FU/LV treatment were accentuated by oxaliplatin. Adverse events were similar in men and women and in patients <65 and ≥65 years of age, but older patients may have been more susceptible to dehydration, diarrhea, hypokalemia, and fatigue.
Acute (lasting fewer than 14 days) or persistent (14 days or greater) neuropathies, often exacerbated by exposure to cold (temperature, objects, or liquids) were associated with oxaliplatin. An acute syndrome of pharyngolaryngeal dysesthesia characterized by dysphagia or dyspnea also occurred. The majority of neurotoxic events were reversible. In any given cycle, at least 30% of patients had a neurotoxic event.
Having an event in one cycle was not predictive of subsequent events, although there were patients who had events with every cycle. The population of patients having an event varied, so that over the course of the study about 75% of all patients had at least one neurotoxic event.
The mean number of acute neurotoxic events per patient was three with a range of 1-12. Of the patients that had neurotoxic events, the acute events tended to occur in the earlier cycles. Persistent events and high-grade events occurred during any cycle, with the net result that proportionately more patients had persistent events during the later cycles.
DISCUSSION
A small but statistically significant improvement in tumor response rate was observed in the combination arm of oxaliplatin, infusional 5-FU, and LV in a population that has no other treatment options. An interim analysis of radiographic TTP, with approximately 50% of events, revealed that TTP was longer in the combination arm. This improvement in response rate and the interim analysis showing a longer radiographic TTP were the bases of approval for oxaliplatin.
The trial results demonstrate that the efficacy of singleagent oxaliplatin is similar to that of infusional 5-FU/LV, and that oxaliplatin should not be used alone in this patient population, except in clinical trials. Caution should be exercised in choosing the regimen if bolus 5-FU is used together with oxaliplatin due to excessive toxicities [7] . One arm of the North Central Cancer Treatment Group study 9741 using bolus 5-FU and oxaliplatin was also closed early due to toxicity.
ENDNOTE
The views expressed are the result of independent work and do not necessarily represent the views and findings of the U.S. FDA.
